Evangelos Terpos

Evangelos Terpos, MD, PhD is a Professor of Haematology in the Department of Clinical Therapeutics in the University of Athens, School of Medicine, Athens, Greece. His main research interest is the biology of plasma cell dyscrasias and especially the biology of bone disease in multiple myeloma (MM). In more than 600 papers in peer-reviewed journals, Dr Terpos has reported the significant role of RANKL and osteoprotegerin axis, CCL-3 (MIP-1alpha), Wnt and TGF-beta signalling in myeloma bone disease and myeloma cell growth. He has studied the predictive value of markers of bone remodelling and osteoclast function in myeloma progression and patients’ survival. He has evaluated the effect of bisphosphonates and different anti-myeloma therapies including ASCT, IMiDs- and bortezomib-based regimens on bone metabolism. He has studied the biology and prevalence of osteonecrosis of the jaw in myeloma patients who receive bisphosphonates. Dr Terpos also works on the role of angiogenesis in MM and Waldenstrom’s Macroglobulinemia, renal impairment in MM, and apoptotic proteins in the clinical outcome of patients with plasma cell dyscrasias. In clinical research, Dr Terpos has participated and participates in all important clinical trials with novel agents (pomalidomide, carfilzomib, ixazomib, daratumumab etc) in the field of multiple myeloma. Dr Terpos has studied also the biology and management of bone disease in thalassemia and sickle-cell disease, as well as of other hematological disorders including hemophilia, Paget's disease and histiocytosis. Dr Terpos is recently very active for the immune response of patients with COVID-19 and of vaccinated healthy individuals and patients with hematology malignancies. Dr Terpos has given lectures at EHA & ASH meetings, International Myeloma Workshops, International Meetings on Cancer-Induced Bone Disease and in several national meetings. He is reviewer of scientific papers in more than 50 medical journals and has reviewed abstracts for EHA and ASH meetings. He is Associate editor for Myeloma in Hemasphere (official journal of EHA) since 2017.